RJX is anticipated to shorten the time to resolution of ARDS by eliminating the contributions pro-inflammatory cytokines IL-6, TNF-α and TGF-β to the systemic and pulmonary inflammatory process. This evidence concerns the gene IL6 and acute respiratory distress syndrome.